Loratadine
Brand names: Clarityn
Loratadine is a non-sedating second-generation oral antihistamine used to relieve the symptoms of allergic rhinitis and chronic urticaria.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a selective peripheral histamine H1-receptor antagonist that blocks histamine-driven allergic symptoms including itch, sneezing, rhinorrhoea, and urticarial weals.
Prescribing in practice
- Dose adjustment is advised in significant hepatic impairment, where clearance is reduced; refer to the SPC and use a children's formulary for paediatric dosing.
- It is generally well tolerated and non-sedating, though occasional drowsiness, headache, and dry mouth can occur.
- Available over the counter for short-term allergy symptom relief as well as on prescription; review current prescribing references for cautions.
Monitoring
Routine monitoring is not required; assess symptom control and tolerability, with caution in hepatic impairment.
Counselling the patient
- This usually relieves allergy symptoms without causing drowsiness, but stop and seek advice if it does affect you.
- It can be taken regularly during periods of allergen exposure such as the pollen season.
Evidence & guidelines
Loratadine and other second-generation antihistamines are recommended first-line for allergic rhinitis and chronic urticaria in NICE and international allergy guidance.
Reference: BSACI; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Difficult Airway Algorithm (DAS) · DAS 2015; Royal College of Anaesthetists
- Major Haemorrhage Protocol · NICE NG24; UK MHP guidelines
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines